Clene Inc. (Clene), a clinical-stage pharmaceutical company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on November 13, 2024. The registration statement pertains to the potential sale of up to 2,351,202 shares of common stock by certain selling securityholders, including shares issuable upon the exercise of warrants. The selling securityholders include entities and individuals such as SymBiosis II, LLC, Armistice Capital Master Fund Ltd., and various directors and officers of Clene. The shares were originally issued as part of private placements that occurred on October 1, 2024. Clene will not receive any proceeds from the sale of shares by the selling securityholders, except for potential proceeds from the exercise of warrants for cash. The company has stated that...Show More

Clene Inc. (Clene), a clinical-stage pharmaceutical company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on November 13, 2024. The registration statement pertains to the potential sale of up to 2,351,202 shares of common stock by certain selling securityholders, including shares issuable upon the exercise of warrants. The selling securityholders include entities and individuals such as SymBiosis II, LLC, Armistice Capital Master Fund Ltd., and various directors and officers of Clene. The shares were originally issued as part of private placements that occurred on October 1, 2024. Clene will not receive any proceeds from the sale of shares by the selling securityholders, except for potential proceeds from the exercise of warrants for cash. The company has stated that it will pay all expenses associated with the registration of the shares, excluding underwriting discounts, commissions, and certain selling securityholder expenses. Clene has also entered into indemnification agreements with its directors and executive officers, and maintains a general liability insurance policy for them. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'CLNN'.